MCID: PNC119
MIFTS: 48

Pancreatic Neuroendocrine Tumor

Categories: Rare diseases, Neuronal diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Pancreatic Neuroendocrine Tumor

MalaCards integrated aliases for Pancreatic Neuroendocrine Tumor:

Name: Pancreatic Neuroendocrine Tumor 53 37
Islet Cell Tumor 53 73
Well-Differentiated Neuroendocrine Neoplasm of Pancreas 53
Well-Differentiated Pancreatic Neuroendocrine Neoplasm 53
Well Differentiated Pancreatic Endocrine Tumor 73
Well-Differentiated Nen of Pancreas 53
Pancreatic Neuroendocrine Neoplasm 53
Well-Differentiated Pancreatic Nen 53
Neuroendocrine Tumor of Pancreas 53
Pancreatic Endocrine Tumor 53
Pancreatic Net 53
Pnet 53

Classifications:



External Ids:

KEGG 37 H00045
UMLS 73 C1337011

Summaries for Pancreatic Neuroendocrine Tumor

NIH Rare Diseases : 53 A pancreatic neuroendocrine tumor, also called an islet cell tumor, is a type of neuroendocrine tumor (NET) that typically arises in the pancreas. However in some cases, a pancreatic NET occurs outside of the pancreas. A NET arises from cells that produce hormones, so the tumor can also produce hormones. It may be benign (not cancerous) or malignant (cancerous). Pancreatic NETs usually grow slowly over many years, but there are fast-growing forms. Pancreatic NETs are called either functional or nonfunctional. A functional pancreatic NET causes specific symptoms because it makes extra hormones, such as gastrin, insulin, or glucagon. Examples of types of functional pancreatic NETs include insulinomas, glucagonomas, gastrinomas, VIPomas, and somatostatinomas. Symptoms depend on the type of hormone being made. A nonfunctional pancreatic NET generally does not cause specific symptoms, but may eventually cause symptoms relating to its location and size as it grows or spreads. Pancreatic NETs can be hard to diagnosis, often not identified until 5 to 10 years after they begin to grow. Most pancreatic NETs are not inherited and occur sporadically in people with no family history of NETs. However, about 10% are associated with a hereditary cancer or tumor syndrome such as multiple endocrine neoplasia type 1 (MEN1), which has autosomal dominant inheritance. Treatment options for each person depend on many factors including the type of tumor, its location, whether it has spread to other parts of the body (metastasized), and symptoms present. Treatment options may include surgery to remove all or part of the tumor (and sometimes the lymph nodes), and/or nonsurgical treatments to shrink the tumor, stop it from growing, or alleviate symptoms. The chance of recovery (prognosis) also depends upon these factors and differs from person to person.

MalaCards based summary : Pancreatic Neuroendocrine Tumor, also known as islet cell tumor, is related to tuberous sclerosis and glioblastoma. An important gene associated with Pancreatic Neuroendocrine Tumor is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are NFAT and Cardiac Hypertrophy and Pathways in cancer. The drugs Miconazole and Sunitinib have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lymph node and liver, and related phenotypes are Decreased cell migration and Increased cell migration

Wikipedia : 76 Pancreatic neuroendocrine tumors (PanNETs, PETs, or PNETs), often referred to as \"islet cell tumors\",... more...

Related Diseases for Pancreatic Neuroendocrine Tumor

Diseases related to Pancreatic Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 tuberous sclerosis 29.4 MTOR PIK3CA
2 glioblastoma 28.5 MEG3 MTOR PIK3CA
3 islet cell tumor 12.4
4 non-functioning pancreatic endocrine tumor 12.4
5 pheochromocytoma--islet cell tumor syndrome 12.3
6 functioning pancreatic endocrine tumor 12.3
7 ewing sarcoma 11.8
8 neuroendocrine tumor 11.6
9 insulinoma 11.6
10 pineoblastoma 11.4
11 von hippel-lindau syndrome 11.4
12 non-functioning neuroendocrine tumor of pancreas 11.4
13 supratentorial primitive neuroectodermal tumor 11.3
14 medulloblastoma 11.2
15 cerebral primitive neuroectodermal tumor 11.1
16 insulinomatosis and diabetes mellitus 11.1
17 serotonin-producing neuroendocrine tumor of pancreas 11.1
18 pancreatitis 11.0
19 multiple endocrine neoplasia 10.4
20 multiple endocrine neoplasia, type i 10.3
21 dermatosis papulosa nigra 10.2 MTOR PIK3CA
22 hemimegalencephaly 10.2 MTOR PIK3CA
23 clear cell adenofibroma 10.2 MTOR PIK3CA
24 ovarian clear cell adenocarcinoma 10.2 MTOR PIK3CA
25 squamous cell carcinoma of the oral tongue 10.1 MKI67 PIK3CA
26 keratosis, seborrheic 10.1 MTOR PIK3CA
27 type i 10.0
28 renal cell carcinoma, nonpapillary 10.0
29 hepatitis 10.0
30 estrogen-receptor positive breast cancer 10.0 MTOR PIK3CA
31 gastrointestinal stromal tumor 10.0
32 duodenitis 10.0
33 megalencephaly 9.9 MTOR PIK3CA
34 kidney cancer 9.9 MEG3 MTOR
35 ovarian epithelial cancer 9.9 MEG3 PIK3CA
36 acute pancreatitis 9.9
37 hypoglycemia 9.9
38 tuberous sclerosis 1 9.9
39 conn's syndrome 9.9
40 carcinoid syndrome 9.9
41 neurofibromatosis, type i 9.9
42 pheochromocytoma 9.9
43 renal cell carcinoma, papillary, 1 9.8 MTOR PIK3CA
44 thrombosis 9.7
45 perivascular epithelioid cell tumor 9.7
46 amyloidosis 9.7
47 retinoblastoma 9.7
48 microinvasive gastric cancer 9.7
49 recurrent acute pancreatitis 9.7
50 rheumatoid arthritis 9.7

Graphical network of the top 20 diseases related to Pancreatic Neuroendocrine Tumor:



Diseases related to Pancreatic Neuroendocrine Tumor

Symptoms & Phenotypes for Pancreatic Neuroendocrine Tumor

GenomeRNAi Phenotypes related to Pancreatic Neuroendocrine Tumor according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.13 FGFR4 MTOR PIK3CA
2 Increased cell migration GR00055-A-3 8.8 FGFR4 MTOR PIK3CA

Drugs & Therapeutics for Pancreatic Neuroendocrine Tumor

Drugs for Pancreatic Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 341031-54-7, 557795-19-4 5329102
3
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
4
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
5
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
6
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 53608-75-6
7 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
8 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Hormones Phase 4,Phase 3,Phase 2,Phase 1
10 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hypoglycemic Agents Phase 4,Phase 2,Phase 1
14 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
18 pancreatin Phase 4,Phase 2,Phase 1,Not Applicable
19 insulin Phase 4,Not Applicable
20 Insulin, Globin Zinc Phase 4,Not Applicable
21 Fluorodeoxyglucose F18 Phase 4,Phase 2
22
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 5310940 9887054 43805 6857599
23
Fluorouracil Approved Phase 2, Phase 3,Phase 3 51-21-8 3385
24
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
25
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
26 lanreotide Approved Phase 3,Phase 2 108736-35-2
27
Streptozocin Approved, Investigational Phase 3,Phase 2 18883-66-4 29327
28
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
29
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3 58-05-9 143 6006
30
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
31 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 1,Not Applicable 59763-91-6
32 Antimetabolites Phase 2, Phase 3,Phase 3,Phase 1
33 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3,Phase 1
34 Angiopeptin Phase 3,Phase 2
35 Pharmaceutical Solutions Phase 3,Phase 2
36 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
37 Dihydroxyphenylalanine Phase 3
38 Dopamine Agents Phase 3
39 Folate Nutraceutical Phase 2, Phase 3,Phase 1
40 Vitamin B9 Nutraceutical Phase 2, Phase 3,Phase 1
41
Metformin Approved Phase 2 657-24-9 14219 4091
42
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
43
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
44
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
45
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
46
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
47
Doxorubicin Approved, Investigational Phase 2,Not Applicable 23214-92-8 31703
48
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
49
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
50
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
3 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
4 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4 sunitinib
5 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
6 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
7 Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour Completed NCT00842348 Phase 3 lanreotide (Autogel formulation)
8 Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours Completed NCT00353496 Phase 3 lanreotide (Autogel formulation);Placebo
9 Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Completed NCT00510068 Phase 3 Everolimus;Everolimus Placebo
10 A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) Recruiting NCT02288377 Phase 2, Phase 3 lanreotide;Placebo
11 Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors Recruiting NCT02589821 Phase 3 Sulfatinib
12 Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET Recruiting NCT02246127 Phase 3 Drug: Everolimus;STZ-5FU
13 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
14 Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Not yet recruiting NCT02705651 Phase 3 Somatostatin-Analog
15 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
16 A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors Terminated NCT00428597 Phase 3 sunitinib malate;Placebo
17 Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs Unknown status NCT02294006 Phase 2 Everolimus plus Octreotide LAR plus Metformin
18 Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors Unknown status NCT01803503 Phase 2 Docetaxel;Sunitinib
19 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer Unknown status NCT02188550 Phase 2 everolimus and letrozole
20 Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors Unknown status NCT02455596 Phase 2 Recombinant anti-tumor and anti-virus protein for injection (Novaferon)
21 BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Completed NCT01658436 Phase 2 BEZ235 (Stage 1)
22 Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Completed NCT01845675 Phase 2 temozolomide or dacarbazine-based chemotherapy, endostatin
23 Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01121562 Phase 2 Sunitinib
24 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours Completed NCT01673906 Phase 2 Diagnostic work up
25 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Completed NCT01024387 Phase 2 AMG 479
26 A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET) Completed NCT02806648 Phase 2 Palbociclib
27 Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT02101918 Phase 2
28 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Completed NCT02231762 Phase 2 Lanreotide Autogel 120 mg;Temozolomide (TMZ)
29 Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas Completed NCT00001165 Phase 2 combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
30 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy Completed NCT00363051 Phase 2 Everolimus 10 mg;Octreotide Depot
31 Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer Completed NCT00001228 Phase 2 Interferon
32 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
33 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Completed NCT02162446 Phase 1, Phase 2 68Ga-OPS202
34 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
35 KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors Completed NCT02250885 Phase 2 Selinexor
36 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
37 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
38 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
39 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
40 Pazopanib as Single Agent in Advanced NETs Completed NCT01280201 Phase 2 Pazopanib
41 Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) Completed NCT00610129 Phase 2 MK-0646
42 The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid Completed NCT00001191 Phase 2 Pantoprazole;Omeprazole
43 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
44 Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases Completed NCT00019786 Phase 2 isolated perfusion;melphalan
45 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer Completed NCT01396382 Phase 2
46 A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor Recruiting NCT03204019 Phase 2 Tegafur and Temozolomide;Tegafur and Temozolomide combined with Thalidomide
47 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors Recruiting NCT02736448 Phase 2 Capecitabine;Lu-PRRT;SS-LAR
48 Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib Recruiting NCT02713763 Phase 2 Sunitinib
49 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Recruiting NCT02893930 Phase 2 Sapanisertib
50 Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Recruiting NCT01465659 Phase 1, Phase 2 temozolomide;pazopanib hydrochloride

Search NIH Clinical Center for Pancreatic Neuroendocrine Tumor

Genetic Tests for Pancreatic Neuroendocrine Tumor

Anatomical Context for Pancreatic Neuroendocrine Tumor

MalaCards organs/tissues related to Pancreatic Neuroendocrine Tumor:

41
Pancreas, Lymph Node, Liver, Lung, Endothelial, Kidney, Pancreatic Islet

Publications for Pancreatic Neuroendocrine Tumor

Articles related to Pancreatic Neuroendocrine Tumor:

(show top 50) (show all 297)
# Title Authors Year
1
Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. ( 29503572 )
2018
2
Reply to: Genotype-Phenotype Pancreatic Neuroendocrine Tumor Relationship in Multiple Endocrine Neoplasia Type 1 Patients: A 23 Year Experience at a Single Institution. ( 29859614 )
2018
3
Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study. ( 29698969 )
2018
4
Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. ( 29330294 )
2018
5
Hepatobiliary and Pancreatic: Malignant pancreatic perivascular epithelioid cell tumor mimicking pancreatic neuroendocrine tumor. ( 29888489 )
2018
6
Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance. ( 29594467 )
2018
7
Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution. ( 29122330 )
2018
8
Prognostic factors of non-functioning pancreatic neuroendocrine tumor revisited: The value of WHO 2010 classification. ( 29536058 )
2018
9
Hypoglycemia in a Patient With a Polyhormonal Pancreatic Neuroendocrine Tumor With Evidence of Endocrine Progenitors. ( 29568813 )
2018
10
Intrapancreatic Accessory Spleen Masquerading as a Pancreatic Neuroendocrine Tumor. ( 29404984 )
2018
11
Simultaneous Glucagon and Vasoactive Intestinal Peptide Producing Pancreatic Neuroendocrine Tumors in a Patient With Multiple Endocrine Neoplasia Type 1: A Case Report and Literature Review. ( 29232343 )
2018
12
Agenesis of dorsal pancreas associated with pancreatic neuroendocrine tumor: a case report and review of the literature. ( 29958547 )
2018
13
Demonstration of 68Ga-prostate-specific Membrane Antigen Uptake in Metastatic Pancreatic Neuroendocrine Tumor. ( 29962731 )
2018
14
Prognostic factors and survival after surgical resection of pancreatic neuroendocrine tumor with validation of established and modified staging systems. ( 29576279 )
2018
15
Cystic pancreatic neuroendocrine tumor. Pancreatic endocrine or neuroendocrine tumor. Endoscopic ultrasonography. ( 29313698 )
2018
16
Letter to the editors regarding: genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: a 23-year experience at a single institution. ( 29338880 )
2018
17
A case of pancreatic neuroendocrine tumor with multiple cystic components of various sizes. ( 29270782 )
2018
18
Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). ( 29325706 )
2018
19
Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression. ( 29521944 )
2018
20
Two-stage resection of a bilateral pheochromocytoma and pancreatic neuroendocrine tumor in a patient with von Hippel-Lindau disease: A case report. ( 29501019 )
2018
21
Fine-needle aspiration of a pancreatic neuroendocrine tumor with prominent rhabdoid features. ( 29359517 )
2018
22
Gastric metastasis from pancreatic neuroendocrine tumor. ( 29634914 )
2018
23
Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis. ( 29140113 )
2018
24
Differentiation between pancreatic metastases from clear cell renal cell carcinoma and pancreatic neuroendocrine tumor using double-echo chemical shift imaging. ( 29500651 )
2018
25
Decreased expression of LKB1 predicts poor prognosis in pancreatic neuroendocrine tumor patients undergoing curative resection. ( 29563804 )
2018
26
Role of surgery in pancreatic neuroendocrine tumor. ( 29629318 )
2018
27
Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. ( 29107104 )
2018
28
Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors. ( 29150024 )
2018
29
Incidental Detection of Asymptomatic Brain Metastases on<sup>18</sup>F-fluoride Positron Emission Tomography/Computed Tomography and<sup>68</sup>Ga DOTANOC Positron Emission Tomography/Computed Tomography in a Patient with Concomitant Breast Carcinoma and a Pancreatic Neuroendocrine Tumor. ( 29398971 )
2018
30
Insulin Expressing Pancreatic Neuroendocrine Tumor Associated With Intratumor Amyloidosis. ( 28648398 )
2017
31
An Elderly Man With Pancreatic Neuroendocrine Tumor and a Cavitary Right Upper Lobe Lung Mass. ( 28599947 )
2017
32
MEG3 Suppresses Human Pancreatic Neuroendocrine Tumor Cells Growth and Metastasis by Down-Regulation of Mir-183. ( 29132136 )
2017
33
Rupture of small cystic pancreatic neuroendocrine tumor with many microtumors. ( 29085235 )
2017
34
Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series. ( 28638801 )
2017
35
Everolimus Effect on Gastrin and Glucagon in Pancreatic Neuroendocrine Tumors. ( 28609362 )
2017
36
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors. ( 28609363 )
2017
37
Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30. ( 28864881 )
2017
38
Late onset asymptomatic pancreatic neuroendocrine tumor - A case report on the phenotypic expansion for MEN1. ( 28736585 )
2017
39
Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: case report and review of the literature. ( 28887784 )
2017
40
Adenocarcinoma versus pancreatic neuroendocrine tumor - case report. ( 29250695 )
2017
41
Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. ( 28371511 )
2017
42
The Long Non-Coding RNA MEG3 is an Epigenetic Determinant of Oncogenic Signaling in Functional Pancreatic Neuroendocrine Tumor Cells. ( 28847847 )
2017
43
Pancreatic Neuroendocrine Tumor Producing Insulin and Vasopressin. ( 28718084 )
2017
44
Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis. ( 29136022 )
2017
45
Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel. ( 29212165 )
2017
46
Diffuse Enlargement of the Pancreas: An Unusual Radiologic Presentation of a Pancreatic Neuroendocrine Tumor. ( 28624649 )
2017
47
Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases. ( 29108359 )
2017
48
Sarcoidosis mimicking metastatic progression of pancreatic neuroendocrine tumor: A case report. ( 28658123 )
2017
49
Pancreatic neuroendocrine tumor: prediction of the tumor grade using CT findings and computerized texture analysis. ( 28766979 )
2017
50
Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. ( 27663587 )
2017

Variations for Pancreatic Neuroendocrine Tumor

Copy number variations for Pancreatic Neuroendocrine Tumor from CNVD:

7 (show all 16)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 36717 1 79269825 120225489 Loss DDA3 Pancreatic endocrine tumor
2 38231 10 1 77700000 Gain RET Pancreatic endocrine tumor
3 40010 10 123100000 127500000 Loss DMBT1 Pancreatic endocrine tumor
4 45931 10 75266020 135228726 Loss PTEN Pancreatic endocrine tumor
5 49582 11 108093559 108239826 Loss ATM Pancreatic endocrine tumor
6 49994 11 112500000 114500000 Loss PPP2R1B Pancreatic endocrine tumor
7 117037 17 70900000 81195210 Loss FAS Pancreatic endocrine tumor
8 151222 20 18623480 62342703 Gain BCAS1 Pancreatic endocrine tumor
9 162982 22 23484416 48053047 Loss CHEK2 Pancreatic endocrine tumor
10 166156 3 1 91700000 Indels Pancreatic endocrine tumor
11 176562 3 49525778 51884070 Loss IFRD2 Pancreatic endocrine tumor
12 179191 3 8700000 16400000 Loss FANCD2 Endocrine pancreatic tumor
13 191665 5 1 46100000 Gain TERT Pancreatic endocrine tumor
14 206334 6 139000000 149000000 Loss Endocrine pancreatic tumor
15 225336 7 45020224 55392724 Gain EGFR Pancreatic endocrine tumor
16 236915 8 18983547 53650298 Loss BNIP3L Pancreatic endocrine tumor

Expression for Pancreatic Neuroendocrine Tumor

Search GEO for disease gene expression data for Pancreatic Neuroendocrine Tumor.

Pathways for Pancreatic Neuroendocrine Tumor

Pathways related to Pancreatic Neuroendocrine Tumor according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.51 FGFR4 MTOR PIK3CA
2 12.48 FGFR4 MTOR PIK3CA
3
Show member pathways
12.33 FGFR4 MTOR PIK3CA
4
Show member pathways
12.01 FGFR4 MTOR PIK3CA
5
Show member pathways
11.85 FGFR4 MTOR PIK3CA
6
Show member pathways
11.76 FGFR4 MTOR
7
Show member pathways
11.65 FGFR4 MTOR PIK3CA
8 11.62 MTOR PIK3CA
9 11.61 MTOR PIK3CA
10
Show member pathways
11.57 MTOR PIK3CA
11
Show member pathways
11.53 FGFR4 MTOR PIK3CA
12 11.45 MTOR PIK3CA
13 11.42 MTOR PIK3CA
14 11.38 MTOR PIK3CA
15
Show member pathways
11.36 MTOR PIK3CA
16 11.34 FGFR4 PIK3CA
17 11.31 MTOR PIK3CA
18 11.28 MTOR PIK3CA
19 11.1 FGFR4 PIK3CA
20 11.08 MTOR PIK3CA
21 10.95 FGFR4 MTOR PIK3CA
22 10.85 MTOR PIK3CA
23 10.63 MTOR PIK3CA

GO Terms for Pancreatic Neuroendocrine Tumor

Cellular components related to Pancreatic Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol 3-kinase complex GO:0005942 8.62 MTOR PIK3CA

Biological processes related to Pancreatic Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.33 FGFR4 MTOR PIK3CA
2 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.32 FGFR4 PIK3CA
3 cardiac muscle contraction GO:0060048 9.26 MTOR PIK3CA
4 negative regulation of macroautophagy GO:0016242 8.96 MTOR PIK3CA
5 anoikis GO:0043276 8.62 MTOR PIK3CA

Molecular functions related to Pancreatic Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.56 FGFR4 MKI67 MTOR PIK3CA
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.16 FGFR4 PIK3CA
3 nucleotide binding GO:0000166 9.13 FGFR4 MTOR NT5E
4 1-phosphatidylinositol-3-kinase activity GO:0016303 8.62 FGFR4 PIK3CA

Sources for Pancreatic Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....